Diasorin SpADSRLF +9.09%69 EV-to-FCF is 12.55 as of Jul. 02, 2026, which is 36% below its 10-year median of 19.76. GuruFocus rates DSRLF with a GF Score™ of 69/100 and a GF Value™ of $95.96 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 72.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Diasorin SpA's Enterprise Value is $4,822 Mil.
Diasorin SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $384 Mil. Therefore, Diasorin SpA's EV-to-FCF for today is 12.55.
The historical rank and industry rank for Diasorin SpA's EV-to-FCF or its related term are showing as below:
DSRLF'
s EV-to-FCF Range Over the Past 10 Years
Min: 11.21 Med: 19.76 Max: 50.88
Current: 12.55
During the past 13 years, the highest EV-to-FCF of Diasorin SpA was 50.88. The lowest was 11.21. And the median was 19.76.
DSRLF's EV-to-FCF is ranked better than 72.16% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.85
vs DSRLF: 12.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diasorin SpA's PE Ratio (TTM) for today is calculated as:
Diasorin SpA's share price for today is $81.00.
Diasorin SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diasorin SpA EV-to-FCF Related Terms
Diasorin SpA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's EV-to-FCF falls into.
Diasorin SpA's current Enterprise Value is $4,822 Mil.
Diasorin SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $384 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (DSRLF) has a EV-to-FCF of 12.55 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diasorin SpA and its competitors. This is 36% below median its historical median of 19.76. Over the past decade, Diasorin SpA's EV-to-FCF has ranged from 11.21 to 50.88. According to the industry distribution chart, Diasorin SpA ranks #27 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 27.8%.
Is Diasorin SpA's EV-to-FCF too high?
Diasorin SpA's current EV-to-FCF of 12.55 is 36% below median its 10-year median of 19.76. Over the past 10 years, this metric has ranged from a low of 11.21 to a high of 50.88. The Medical Diagnostics & Research industry median EV-to-FCF is 22.85. Diasorin SpA's value of 12.55 is 45.1% below this industry median. Based on the distribution chart, Diasorin SpA ranks #27 out of 97 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #27 out of 97 companies for EV-to-FCF. This puts Diasorin SpA in the upper half of its industry. The industry median EV-to-FCF is 22.85. Diasorin SpA's value of 12.55 is 45.1% below this benchmark. Historically, Diasorin SpA's own EV-to-FCF has ranged from 11.21 to 50.88 over the past decade. While the company's 10-year median is 19.76 vs. the industry median of 22.85, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.85, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current EV-to-FCF of 12.55 is 45.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EV-to-FCF is 12.55, which is 36% below median its own 10-year median of 19.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (DSRLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.96, compared to a current price of $81.00 — trading 15.6% below its estimated fair value. The current EV-to-FCF is 12.55, which is 36% below median its 10-year median of 19.76 and 45.1% below the Medical Diagnostics & Research industry median of 22.85. Diasorin SpA's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Diasorin SpA (DSRLF), the current EV-to-FCF is 12.55 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (DSRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of $81.00 is trading 15.6% below its estimated GF Value™ of $95.96.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for DSRLF:
EV-to-FCF: 12.55 (36% below median its 10-year median of 19.76)
GF Value™: $95.96 vs. price of $81.00 (15.6% below fair value)
Industry Position: 45.1% below the Medical Diagnostics & Research median (#27 of 97)
No single metric tells the full story. See the DSRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
69GF Score
Get the complete analysis for DSRLF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSRLF has been successfully added to your 
